Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 205Breast Neoplasms 187Neoplasms 167Leukemia, Myeloid, Acute 164Multiple Myeloma 157Lymphoma 120Melanoma 117Neoplasm Metastasis 114Lymphoma, Non-Hodgkin 110Prostatic Neoplasms 109Leukemia 107Colorectal Neoplasms 96Recurrence 91Leukemia, Lymphocytic, Chronic, B-Cell 90Pancreatic Neoplasms 85Ovarian Neoplasms 85Myelodysplastic Syndromes 83Lung Neoplasms 83Lymphoma, Follicular 78Glioblastoma 78Precursor Cell Lymphoblastic Leukemia-Lymphoma 77Lymphoma, Large B-Cell, Diffuse 77Hodgkin Disease 69Lymphoma, Mantle-Cell 65Carcinoma, Renal Cell 62Brain Neoplasms 56Small Cell Lung Carcinoma 55Squamous Cell Carcinoma of Head and Neck 54Triple Negative Breast Neoplasms 52Sarcoma 52

Interventions

Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Drug Resistant Epilepsy × Clear all
NCT02332655 2022-03-02

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 1/2 Completed
5 enrolled 8 charts

Drug Resistant Epilepsy, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡